A German family with glucocorticoid-remediable aldosteronism

Nephrology Dialysis Transplantation

Volumn 22, Issue 4, 2007, Pages 1123-1130

  Vonend, Oliver ^a,c   Altenhenne, Christian ^a,c   Büchner, Nicolaus J ^a,c   Dekomien, Gabriele ^a   Maser Gluth, Christiane ^b   Weiner, Stefan M ^a,c   Sellin, Lorenz ^a,c   Hofebauer, Stefan ^a,c   Epplen, Jörg T ^a   Rump, Lars Christian ^a,c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

18 OH cortisol; Ambulatory blood pressure; Eplerenone; Glucocorticoid remediable aldosteronism; Primary hyperaldosteronism; Secondary hypertension

Indexed keywords

18 HYDROXYHYDROCORTISONE; ALDOSTERONE; BENAZEPRIL; BISOPROLOL; CALCIUM ANTAGONIST; DEXAMETHASONE; EPLERENONE; HYDROCORTISONE; POTASSIUM; RENIN; SODIUM CHLORIDE; URAPIDIL;

ADULT; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE URINE LEVEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; CASE REPORT; CHIMERA; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FAMILY; GENE IDENTIFICATION; GERMANY; GLUCOCORTICOID REMEDIABLE ALDOSTERONISM; HOSPITAL ADMISSION; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERTENSION; MALE; MICROALBUMINURIA; PHENOTYPE; PLASMA RENIN ACTIVITY; POLYMERASE CHAIN REACTION; POTASSIUM BLOOD LEVEL; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SALT LOADING; SCREENING TEST; SOUTHERN BLOTTING; TREATMENT DURATION;

EID: 34047131750     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl706     Document Type: Article

References (29)

1. Gordon RD. Primary aldosteronism-actual epidemics or false alarm? Arq Bras Endocrinol Metabol 2004; 48: 666-673
2. Stowasser M, Gordon RD, Gunasekera TG et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens 2003; 21: 2149-2157
3. Seiler L, Rump LC, Schulte-Monting J et al. Diagnosis of primary aldosteronism: Value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol 2004; 150: 329-337
4. Buchner N, Vonend O, Rump LC. Pathophysiology of hypertension: What's New? Herz 2006; 31: 294-302
5. Plouin PF, Amar L, Chatellier G. Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension. Nephrol Dial Transplant 2004; 19: 774-777
6. Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1999; 84: 4341-4344
7. Luft FC. Mendelian forms of human hypertension and mechanisms of disease. Clin Med Res 2003; 1: 291-300
8. Rich GM, Ulick S, Cook S, Wang JZ, Lifton RP, Dluhy RG. Glucocorticoid-remediable aldosteronism in a large kindred: Clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann Intern Med 1992; 116: 813-820
9. Ding W, Liu L, Hu R, Xu M, Chen J. Clinical and gene mutation studies on a Chinese pedigree with glucocorticoidremediable aldosteronism. Chin Med J (Engl) 2002; 115: 979-982
10. Yokota K, Ogura T, Kishida M et al. Japanese family with glucocorticoid-remediable aldosteronism diagnosed by long-polymerase chain reaction. Hypertens Res 2001; 24: 589-594
11. Mulatero P, di Cella SM, Williams TA et al. Glucocorticoid remediable aldosteronism: Low morbidity. J Clin Endocrinol Metab 2002; 87: 3187-3191
12. Fallo F, Pilon C, Williams TA et al. Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism. J Hum Hypertens 2004; 18: 47-51
13. Magni P, Motta M. Aldosterone receptor antagonists: Biology and novel therapeutic applications. Curr Hypertens Rep 2005; 7: 206-211
14. Rossi GP, Sacchetto A, Chiesura-Corona M et al. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 2001; 86: 1083-1090
15. Vecsei P, Abdelhamid S, Mittelstadt GV, Lichtwald K, Haack D, Lewicka S. Aldosterone metabolites and possible aldosterone precursors in hypertension. J Steroid Biochem 1983; 19: 345-351
16. Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966; 95: 1109-1119
17. Lifton RP, Dluhy RG, Powers M et al. A chimaeric 11 beta-hydroxylase/ aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355: 262-265
18. Pizzolo F, Trabetti E, Guarini P et al. Glucocorticoid remediable aldosteronism (GRA) screening in hypertensive patients from a primary care setting. J Hum Hypertens 2005; 19: 325-327
19. Adler G, Widecka K, Peczkowska M et al. Genetic screening for glucocorticoid-remediable aldosteronism (GRA): Experience of three clinical centres in Poland. J Appl Genet 2005; 46: 329-332
20. Gates LJ, Benjamin N, Haites NE, MacConnachie AA, McLay JS. Is random screening of value in detecting glucocorticoid-remediable aldosteronism within a hypertensive population? J Hum Hypertens 2001; 15: 173-176
21. Litchfield WR, New MI, Coolidge C, Lifton RP, Dluhy RG. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1997; 82: 3570-3573
22. Mosso L, Gomez-Sanchez CE, Foecking MF, Fardella C. Serum 18-hydroxycortisol in primary aldosteronism, hypertension, and normotensives. Hypertension 2001; 38: 688-691
23. Mulatero P, Veglio F, Pilon C et al. Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J Clin Endocrinol Metab 1998; 83: 2573-2575
24. Fardella CE, Mosso L, Gomez-Sanchez C et al. Primary hyperaldosteronism in essential hypertensives: Prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867
25. Dluhy RG, Anderson B, Harlin B, Ingelfinger J, Lifton R. Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood. J Pediatr 2001; 138: 715-720
26. McMahon GT, Dluhy RG. Glucocorticoid-remediable aldosteronism. Arq Bras Endocrinol Metabol 2004; 48: 682-686
27. Rump LC. Secondary rise of albuminuria under AT1-receptor Blockade - what is the potential role of aldosterone escape? Nephrol Dial Transplant 2006 [Epub ahead of print]
28. Arima S, Kohagura K, Xu HL et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003; 14: 2255-2263
29. Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun 1995; 207: 565-571